Helen Gogas1, John M Kirkwood. 1. First Department of Internal Medicine, University of Athens, Greece. hgogas@hol.gr
Abstract
PURPOSE OF REVIEW: There is a critical need for greater understanding of the immunological and disease-related variables that predict clinical benefit from interferon alfa-2b. The identification of predictive markers that permit selection of patients who are most likely to benefit from interferon alfa would allow us to avoid exposing nonresponsive patients to the toxicity of treatment unassociated with benefit, and to double or treble the therapeutic index by excluding more than half of patients who are now offered this therapy, but are not able to benefit. RECENT FINDINGS: Subgroup analyses of the European Organization for Research and Treatment of Cancer adjuvant trials, translational research studies in tissue from the neoadjuvant high-dose interferon trial, corollary serum and DNA studies of E1690, E1694, E2696, European Organization for Research and Treatment of Cancer 18952 and the Hellenic Cooperative Oncology Group are discussed. SUMMARY: These findings should be further validated in prospective adjuvant trials and corroborated in larger patient samples.
PURPOSE OF REVIEW: There is a critical need for greater understanding of the immunological and disease-related variables that predict clinical benefit from interferon alfa-2b. The identification of predictive markers that permit selection of patients who are most likely to benefit from interferon alfa would allow us to avoid exposing nonresponsive patients to the toxicity of treatment unassociated with benefit, and to double or treble the therapeutic index by excluding more than half of patients who are now offered this therapy, but are not able to benefit. RECENT FINDINGS: Subgroup analyses of the European Organization for Research and Treatment of Cancer adjuvant trials, translational research studies in tissue from the neoadjuvant high-dose interferon trial, corollary serum and DNA studies of E1690, E1694, E2696, European Organization for Research and Treatment of Cancer 18952 and the Hellenic Cooperative Oncology Group are discussed. SUMMARY: These findings should be further validated in prospective adjuvant trials and corroborated in larger patient samples.
Authors: S Karakhanova; E Ryschich; B Mosl; S Harig; D Jäger; J Schmidt; W Hartwig; J Werner; A V Bazhin Journal: Br J Cancer Date: 2015-03-17 Impact factor: 7.640